scholarly article | Q13442814 |
P356 | DOI | 10.1021/ACS.JMEDCHEM.7B00360 |
P698 | PubMed publication ID | 28665128 |
P50 | author | Ken A. Brameld | Q42723561 |
P2093 | author name string | J Michael Bradshaw | |
David M Goldstein | |||
Eleni Venetsanakos | |||
Timothy D Owens | |||
Mary E Gerritsen | |||
Jin Shu | |||
Danny Tam | |||
David G Loughhead | |||
Erik Verner | |||
Kwan Leung | |||
Vernon T Phan | |||
Dane E Karr | |||
Jens Oliver Funk | |||
Tony Ton | |||
Jacob LaStant | |||
P433 | issue | 15 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 6516-6527 | |
P577 | publication date | 2017-06-30 | |
P1433 | published in | Journal of Medicinal Chemistry | Q900316 |
P1476 | title | Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors. | |
P478 | volume | 60 |
Q93382470 | C11, a novel fibroblast growth factor receptor 1 (FGFR1) inhibitor, suppresses breast cancer metastasis and angiogenesis |
Q91995280 | Covalent Inhibition in Drug Discovery |
Q104111296 | DW14383 is an irreversible pan-FGFR inhibitor that suppresses FGFR-dependent tumor growth in vitro and in vivo |
Q64118758 | Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines |
Q92879928 | Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors |
Q88959338 | Pyrazolo[1,5-a]pyrimidine TRPC6 antagonists for the treatment of gastric cancer |
Q60302361 | Structure, activation and dysregulation of fibroblast growth factor receptor kinases: perspectives for clinical targeting |
Q62230924 | TAS-120 Cancer Target Binding: Defining Reactivity and Revealing the First Fibroblast Growth Factor Receptor 1 (FGFR1) Irreversible Structure |
Q93048955 | Targeting the Oncogenic FGF-FGFR Axis in Gastric Carcinogenesis |
Search more.